Sales & Marketing Evolving HCP access requires a new connected approach to bui... Specialty medicines – treatments designed for very small patient populations with complex and rare conditions – are on the rise.
R&D In conversation with Chris Moore: Declining HCP access During the 10th anniversary of the Veeva R&D and Quality Summit, held in Madrid in June, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to d
Market Access Shifting HCP access calls for new field tactics globally Even before COVID-19 pushed access to an all-time low, access had been declining
News Sobi adds rare lymphoma drug with $580m Innate tie-up Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.